Mathematical model of sarcoidosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 45, 2014, Pages 16065-16070

  Hao, Wenrui ^a   Crouser, Elliott D ^a   Friedman, Avner ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Granuloma; Math modeling; Sarcoidosis

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; GRANULOMA; HUMAN; INFLAMMATORY CELL; LUNG PARENCHYMA; LUNG SARCOIDOSIS; MACROPHAGE; MATHEMATICAL MODEL; MEDIASTINUM LYMPH NODE; REGULATORY T LYMPHOCYTE; TH17 CELL; BIOLOGICAL MODEL; IMMUNOLOGY; LUNG; LYMPH NODE; MEDIASTINUM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SARCOIDOSIS, PULMONARY;

GRANULOMA; HUMANS; LUNG; LYMPH NODES; MEDIASTINUM; MODELS, IMMUNOLOGICAL; SARCOIDOSIS, PULMONARY;

EID: 84909594627     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1417789111     Document Type: Article

References (45)

1. Crouser ED, et al. (2010) The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-alpha therapy. Chest 137(6):1432-1435.
2. Mehta D, et al. (2008) Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 133(6):1426-1435.
3. Patel MR, et al. (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120(20):1969-1977.
4. Richie RC (2005) Sarcoidosis: A review. J Insur Med 37(4):283-294.
5. Isler P, de Rochemonteix BG, Songeon F, Boehringer N, Nicod LP (1999) Interleukin-12 production by human alveolar macrophages is controlled by the autocrine production of interleukin-10. Am J Respir Cell Mol Biol 20(2):270-278.
6. Fehrenbach H, et al. (2003) Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 21(3):421-428.
7. Ziegenhagen MW, et al. (1997) Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 156(5):1586-1592.
8. Toossi Z, et al. (1996) Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes. J Immunol 156(9):3461-3468.
9. Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18(1):60-65.
10. Nonaka M, et al. (2009) Synergistic induction of macrophage inflammatory protein-3α;/CCL20 production by interleukin-17A and tumor necrosis factor-α; in nasal polyp fibroblasts. World Allergy Organ J 2(10):218-223.
11. Kambouchner M, et al. (2011) Lymphatic and blood microvasculature organisation in pulmonary sarcoid granulomas. Eur Respir J 37(4):835-840.
12. Antoniou KM, et al. (2006) Upregulation of Th1 cytokine profile (IL-12, IL-18) in bronchoalveolar lavage fluid in patients with pulmonary sarcoidosis. J Interferon Cytokine Res 26(6):400-405.
13. Brooks DG, Walsh KB, Elsaesser H, Oldstone MB (2010) IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc Natl Acad Sci USA 107(7):3018-3023.
14. Iellem A, et al. (2001) Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+) CD25 (+) regulatory T cells. J Exp Med 194(6):847-853.
15. Qin H, et al. (2009) TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol 183(1):97-105.
16. Viallard JF, et al. (1999) Th1(IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 115(1):189-195.
17. Laurence A, et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3):371-381.
18. Tischner D, Wiegers GJ, Fiegl H, Drach M, Villunger A (2012) Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. Cell Death Differ 19(8):1277-1287.
19. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA (2007) IL-2 is essential for TGF-beta to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178(4):2018-2027.
20. Khalil N, Corne S, Whitman C, Yacyshyn H (1996) Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol 15(2):252-259.
21. Li MO, Wan YY, Flavell RA (2007) T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26(5):579-591.
22. Crouser ED, et al. (2009) Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 179(10):929-938.
23. Wikén M, et al. (2010) No evidence of altered alveolar macrophage polarization, but reduced expression of TLR2, in bronchoalveolar lavage cells in sarcoidosis. Respir Res 11:121.
24. Robinson BW, McLemore TL, Crystal RG (1985) Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 75(5):1488-1495.
25. Heidenreich S, Gong JH, Schmidt A, Nain M, Gemsa D (1989) Macrophage activation by granulocyte/macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor-alpha and prostaglandin E2. J Immunol 143(4):1198-1205.
26. Pueringer RJ, Schwartz DA, Dayton CS, Gilbert SR, Hunninghake GW (1993) The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest 103(3):832-838.
27. Joller N, et al. (2014) Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 40(4):569-581.
28. Valencia X, et al. (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108(1):253-261.
29. Deenick EK, Tangye SG (2007) Autoimmunity: IL-21: A new player in Th17-cell differentiation. Immunol Cell Biol 85(7):503-505.
30. McGovern JL, et al. (2012) Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 64(10):3129-3138.
31. Rahim SS, Khan N, Boddupalli CS, Hasnain SE, Mukhopadhyay S (2005) Interleukin-10(IL-10) mediated suppression of IL-12 production in RAW 264.7 cells also involves c-rel transcription factor. Immunology 114(3):313-321.
32. Galve-de Rochemonteix B, Nicod LP, Dayer JM (1996) Tumor necrosis factor soluble receptor 75: the principal receptor form released by human alveolar macrophages and monocytes in the presence of interferon gamma. Am J Respir Cell Mol Biol 14(3):279-287.
33. Oliver JC, et al. (1993) Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 12(2):115-120.
34. Hallsworth MP, Soh CP, Lane SJ, Arm JP, Lee TH (1994) Selective enhancement of GM-CSF, TNF-alpha, IL-1 beta and IL-8 production by monocytes and macrophages of asthmatic subjects. Eur Respir J 7(6):1096-1102.
35. Burke RR, Stone CH, Havstad S, Rybicki BA (2009) Racial differences in sarcoidosis granuloma density. Lung 187(1):1-7.
36. Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N (2008) Tumor necrosis factoralpha inhibitor treatment for sarcoidosis. Ther Clin Risk Manag 4(6):1305-1313.
37. King TE, Flaherty KR, Hollingsworth H (2014) Clinical manifestations and diagnosis of pulmonary sarcoidosis. Available at www.uptodate.com/contents/clinical-manifestationsand-diagnosis-of-pulmonary-sarcoidosis. Accessed July 25, 2014.
38. Baughman RP, et al.; Sarcoidosis Investigators (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795-802.
39. Zissel G, Homolka J, Schlaak J, Schlaak M, Müller-Quernheim J (1996) Antiinflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 154(3 Pt 1):713-719.
40. Idali F, et al. (2006) Reduced Th1 response in the lungs of HLA-DRB1∗0301 patients with pulmonary sarcoidosis. Eur Respir J 27(3):451-459.
41. Hata M, Sugisaki K, Miyazaki E, Kumamoto T, Tsuda T (2007) Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. Intern Med 46(17):1387-1393.
42. Jonth AC, et al.; ACCESS Group (2007) TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. J Immunol 179(6):4255-4262.
43. Day J, Friedman A, Schlesinger LS (2009) Modeling the immune rheostat of macrophages in the lung in response to infection. Proc Natl Acad Sci USA 106(27):11246-11251.
44. Thillai M, et al. (2012) Sarcoidosis and tuberculosis cytokine profiles: Indistinguishable in bronchoalveolar lavage but different in blood. PLoS ONE 7(7):e38083.
45. Bloom CI, et al. (2013) Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS ONE 8(8):e70630.